This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In reference to “Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review,” Parsons et al. relate their concerns about the study's methodology and conclusions. The authors suggested a possible reporting bias for studies of pregabalin as there were several unpublished studies or studies without results on clinicaltrials.gov that were not included. Parsons et al. explain that these results were published as a primary analyses, were included as pooled data in secondary analyses, or are currently under review for publication. Parsons et al. provide detailed e-tables of these studies (available online). Authors Waldfogel et al. appreciate Pfizer's commitment to meeting publication guidelines and note that the pooled analyses were not included in their review because they did not meet the eligibility criteria. In their review, Waldfogel et al. concluded that there was weak evidence supporting the use of pregabalin. Parsons et al. counter that many professional societies either endorse pregabalin as a first-line treatment for diabetic peripheral neuropathy (DPN) or have determined there is strong evidence to support its use in DPN. Authors Waldfogel et al. note that the professional societies' recommendations were based on data from 2013 and their analysis included more recent data. Finally, Waldfogel et al. used quality of life as an endpoint. Parsons et al. point out that since quality of life is not a primary endpoint required by drug regulatory agencies, the studies were not powered or designed to adequately investigate that measurement. The authors agree, but call for more detailed reporting of secondary outcomes in future studies.
In reference to “Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review,” Parsons et al. relate their concerns about the study's methodology and conclusions. The authors suggested a possible reporting bias for studies of pregabalin as there were several unpublished studies or studies without results on clinicaltrials.gov that were not included.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
